SQ22536
Selleck Chemicals
SKU:S8283-10MG
Couldn't load pickup availability

SQ22536 is an inhibitor linked to GPCR Signaling and related pathway-oriented research. It is especially relevant in biochemical and cell-based models, where defined compound exposure can be linked to receptor-driven second-messenger signaling and desensitization dynamics.
The pathway annotation connects SQ22536 to GPCR Signaling, supporting experiments that monitor receptor-driven second-messenger signaling and desensitization dynamics across biochemical, cellular, or phenotypic assay formats. This context is compatible with ligand-response, cAMP, calcium-flux, and receptor-pharmacology assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. When a fully resolved mechanism is unavailable, parallel readouts such as viability, reporter activity, morphology, localization, or biochemical conversion can still help position the compound experimentally.
Research Applications
- Pathway perturbation studies connected to GPCR Signaling
- Concentration-response inhibition and target-dependence studies
- Combination studies with orthogonal perturbagens
- Mechanism-oriented follow-up using biochemical and cellular endpoints
Overall, SQ22536 is well suited to pathway-oriented studies that need a defined compound input for GPCR Signaling readouts in biochemical and cell-based models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Pathways:
- GPCR Signaling
- CAS No.:
- 17318-31-9
- Molecular Weight:
- 205.22
- Formula:
- C₉H₁₁N₅O
- SMILES:
- C1CC(OC1)N2C=NC3=C(N=CN=C32)N
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.